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Background: The second Medical, Angioplasty, or Surgery Study (MASS II) compared the long-term effects of medical treatment (MT), angioplasty 
(PCI), or surgical strategies (CABG) among patients with stable angina symptoms of multivessel coronary artery disease (CAD) and preserved 
ventricular function who were appropriate candidates for all 3 therapies. Plasma lipids are important risk factors for cardiovascular events in 
CAD patients, especially in diabetics. We showed previously that the TG/HDL ratio was the only parameter independently associated with major 
cardiovascular events (MACE; overall death, myocardial infarction, and unstable angina that required myocardial revascularization) in patients after 
the 10-year follow up of stable CAD patients in the MASS II. In this analysis we evaluated the association of plasma lipids with MACE in diabetic 
patients after a 10-year follow-up of the MASS II.
Methods: The data of 200 patients of the MASS II, 100 diabetics and 100 non diabetics, were analyzed for risk factors and plasma lipids levels. 
The levels of fasting plasma lipids were determined at baseline and 6 months after randomization. It was instituted in all study patient groups the 
same lipid therapy. Concentrations of total cholesterol, HDL, non-HDL and LDL-cholesterol as well as LDL/HDL, and TG/HDL ratios were divided 
according to distribution quartiles. The association of plasma lipids at baseline and at 6 months with MACE was determined by Cox regression 
models.
Results: The patients were followed up for an average of 11.4 years. In the subgroup of diabetic patients, after adjustment for confounders, older 
age (> 65 years old), randomized treatment for CAD (CABG vs. MT) and the TG/HDL ratio determined at 6 months were independently associated 
with MACE. There was no association between MACE and other plasma lipids.
Conclusions: The TG/HDL remains as a lipid parameter independently associated with MACE in diabetic patients after the 10-year follow up of 
stable CAD patients in the MASS II.
